Income Tax Expense (Benefit) in USD of Ambrx Biopharma Cayman, Inc. from 2019 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Income Tax Expense (Benefit) history and change rate from 2019 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Jun 2023 was $305K, a 136% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2022 was $1.94M, a 193600% increase from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2021 was $1K, unchanged from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2020 was $1K.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $305K +$176K +136% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $73K -$1.51M -95.4% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q2 2022 $129K 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $1.59M 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023

Ambrx Biopharma Cayman, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $1.94M +$1.94M +193600% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023
2021 $1K $0 0% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 $1K +$3K 01 Jan 2020 31 Dec 2020 20-F 26 Apr 2022
2019 -$2K 01 Jan 2019 31 Dec 2019 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.